Quality of Life in Patients With Congenital Afibrinogenemia
NCT ID: NCT03484065
Last Updated: 2020-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
250 participants
OBSERVATIONAL
2016-06-30
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Afibrinogenemia
Questionnaire quality of life
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire quality of life
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient unable to understand the questionnaire
8 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Casini Alessandro
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alessandro Casini, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospitals of Geneva
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Orange Count
Orange, California, United States
Cohen Children's Medical Center
New Hyde Park, New York, United States
Béni Messous
Algiers, , Algeria
University of Calgary
Calgary, , Canada
Cairo University Pediatric Hospital
Cairo, , Egypt
Chru Lille
Lille, , France
Universitats Kilinikum Frankfurt
Frankfurt, , Germany
Dr von Haumer Children's Hospital
Munich, , Germany
St John Medical College Hospital
Bangalore, , India
All India Institute of Medical Sciences
New Delhi, , India
Sapienza Università di Roma
Roma, , Italy
University School of Medicine
Hamamatsu, , Japan
Kuwait University
Kuwait City, , Kuwait
Hotel Dieu-de-France
Beirut, , Lebanon
St George Hospital
Beirut, , Lebanon
Hopital d'Enfants de Rabat
Rabat, , Morocco
Radboud University Medical Centre
Nijmegen, , Netherlands
National Institute Of Blood Disease and Bone Marrow Transplantation
Karachi, , Pakistan
Institute of Hematology and Transfusion Medicine
Warsaw, , Poland
University Clinical Center
Belgrade, , Serbia
National Centre of Hemostasis and Thrombosis
Martin, , Slovakia
Hospital Universitari i Politecnic La Fe
Valencia, , Spain
Inselspital
Bern, , Switzerland
University Hospitals of Geneva
Geneva, , Switzerland
Hopital d'Enfants Bechir Hamza
Tunis, , Tunisia
Uludag University
Bursa, , Turkey (Türkiye)
Cerrahpasa Faculty of Medicine
Istanbul, , Turkey (Türkiye)
Erciyes University
Kayseri, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Casini A, von Mackensen S, Santoro C, Djambas Khayat C, Belhani M, Ross C, Dorgalaleh A, Naz A, Unal E, Abdelwahab M, Lozeron ED, Trillot N, Susen S, Peyvandi F, de Moerloose P; QualyAfib Study Group. Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood. 2021 Jun 3;137(22):3127-3136. doi: 10.1182/blood.2020009472.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-00447
Identifier Type: -
Identifier Source: org_study_id